BLOOD, LYMPH AND RELATED CONDITIONS:@0.084848:0.038601:0.564720:0.038601:0.564720:0.019343:0.084848:0.019343:0.013500:0.010866:0.020438:0.020438:0.017498:0.006515:0.006515:0.008735:0.013923:0.021613:0.013923:0.016063:0.006515:0.017404:0.017404:0.017498:0.006515:0.014276:0.012606:0.010866:0.015466:0.010019:0.012606:0.017498:0.006515:0.019121:0.020438:0.017404:0.017498:0.005315:0.010019:0.005315:0.020438:0.017404:0.011712
92:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
AIDS compared with immunosuppressed :@0.121195:0.094740:0.480505:0.094740:0.480505:0.080735:0.121195:0.080735:0.012657:0.003866:0.012726:0.008518:0.011049:0.011067:0.011203:0.016044:0.011665:0.011682:0.005077:0.011118:0.011716:0.011049:0.014214:0.003421:0.005798:0.010434:0.011049:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.006636:0.010399:0.011665:0.011665:0.005082:0.011118:0.006636:0.006636:0.011118:0.011716:0.004738
transplant recipients: a meta-analysis. :@0.121195:0.108863:0.480470:0.108863:0.480470:0.094857:0.121195:0.094857:0.005798:0.005148:0.011682:0.010434:0.006636:0.011665:0.003421:0.011682:0.010434:0.005798:0.019174:0.005078:0.011118:0.011067:0.003421:0.011665:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.019174:0.011682:0.019174:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738:0.004738
Lancet:@0.121195:0.122986:0.179196:0.122986:0.179196:0.108980:0.121195:0.108980:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798
. 2007;370(9581):59-67.  doi:10.1016/:@0.179196:0.122986:0.475750:0.122986:0.475750:0.108980:0.179196:0.108980:0.004738:0.008484:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009496:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738:0.004738:0.003775:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475
S0140-6736(07)61050-2.:@0.121195:0.137108:0.310044:0.137108:0.310044:0.123103:0.121195:0.123103:0.008518:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
9. :@0.084848:0.151231:0.103800:0.151231:0.103800:0.137226:0.084848:0.137226:0.009476:0.004738:0.004738
 Landgren O, Kyle RA,  Pfeiffer RM, :@0.121195:0.151231:0.424093:0.151231:0.424093:0.137226:0.121195:0.137226:0.000000:0.007902:0.011682:0.010434:0.011716:0.011511:0.005075:0.011118:0.010434:0.009835:0.014864:0.004738:0.009835:0.010109:0.009168:0.003421:0.011118:0.009835:0.010382:0.012657:0.004738:0.004738:0.005087:0.010126:0.005371:0.011118:0.003421:0.005417:0.005371:0.011118:0.005148:0.009835:0.010382:0.015719:0.004738:0.004738
et al:@0.429190:0.151231:0.471044:0.151231:0.471044:0.137226:0.429190:0.137226:0.011118:0.005798:0.009835:0.011682:0.003421
. :@0.471044:0.151231:0.480520:0.151231:0.480520:0.137226:0.471044:0.137226:0.004738:0.004738
Monoclonal  gammopathy  of  undeter-:@0.121195:0.165354:0.475751:0.165354:0.475751:0.151349:0.121195:0.151349:0.015719:0.011203:0.010434:0.011203:0.011067:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738:0.012449:0.011511:0.011682:0.016044:0.016044:0.011203:0.011665:0.011682:0.005798:0.010434:0.009168:0.004738:0.012454:0.011203:0.005371:0.004738:0.012454:0.010399:0.010434:0.011716:0.011118:0.005798:0.011118:0.005131:0.005679
mined  significance  (MGUS)  consistently :@0.121195:0.179477:0.480494:0.179477:0.480494:0.165472:0.121195:0.165472:0.016044:0.003421:0.010434:0.011118:0.011716:0.004738:0.010127:0.006636:0.003421:0.011511:0.010434:0.003421:0.004165:0.004165:0.011067:0.011682:0.010434:0.011067:0.011118:0.004738:0.010126:0.006312:0.015719:0.014915:0.011203:0.008518:0.006312:0.004738:0.010129:0.011067:0.011203:0.010434:0.006636:0.003421:0.006636:0.005798:0.011118:0.010434:0.005798:0.003421:0.009168:0.004738
precedes  multiple myeloma:  a prospec-:@0.121195:0.193600:0.475767:0.193600:0.475767:0.179595:0.121195:0.179595:0.011665:0.005080:0.011118:0.011067:0.011118:0.011716:0.011118:0.006636:0.004738:0.005395:0.016044:0.010399:0.003421:0.005798:0.003421:0.011665:0.003421:0.011118:0.010143:0.016044:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.004738:0.004738:0.005395:0.011682:0.010143:0.011665:0.005082:0.011203:0.006636:0.011665:0.011118:0.011067:0.005679
tive study. :@0.121195:0.207723:0.214380:0.207723:0.214380:0.193717:0.121195:0.193717:0.005798:0.003421:0.009476:0.011118:0.010177:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
Blood:@0.219819:0.207723:0.267181:0.207723:0.267181:0.193717:0.219819:0.193717:0.009818:0.003421:0.011203:0.011203:0.011716
. 2009;113(22):5412-5417. :@0.267181:0.207723:0.480472:0.207723:0.480472:0.193717:0.267181:0.193717:0.004738:0.010177:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009510:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
doi:10.1182/blood-2008-12-194241.:@0.121195:0.221846:0.406034:0.221846:0.406034:0.207840:0.121195:0.207840:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.011665:0.003421:0.011203:0.011203:0.011716:0.005679:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
10.   Rajkumar SV. Prevention  of progression :@0.084848:0.235968:0.480515:0.235968:0.480515:0.221963:0.084848:0.221963:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010382:0.011682:0.003472:0.008586:0.010399:0.016044:0.011682:0.005148:0.013615:0.008518:0.010724:0.004738:0.013615:0.010126:0.005075:0.011118:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.004738:0.008865:0.011203:0.005371:0.013615:0.011665:0.005080:0.011203:0.011511:0.005071:0.011118:0.006636:0.006636:0.003421:0.011203:0.010434:0.004738
in monoclonal gammopathy of unde-:@0.121195:0.250091:0.475758:0.250091:0.475758:0.236086:0.121195:0.236086:0.003421:0.010434:0.014864:0.016044:0.011203:0.010434:0.011193:0.011067:0.003421:0.011203:0.010434:0.011682:0.003421:0.014864:0.011511:0.011682:0.016044:0.016044:0.011203:0.011665:0.011682:0.005798:0.010434:0.009168:0.014864:0.011203:0.005371:0.014864:0.010399:0.010434:0.011716:0.011118:0.005679
termined  significance. :@0.121195:0.264214:0.317066:0.264214:0.317066:0.250209:0.121195:0.250209:0.005798:0.011118:0.005617:0.016044:0.003421:0.010434:0.011118:0.011716:0.004738:0.007271:0.006636:0.003421:0.011511:0.010434:0.003421:0.004165:0.004165:0.011067:0.011682:0.010434:0.011067:0.011118:0.004738:0.004738
Clin Cancer Res:@0.324326:0.264214:0.471013:0.264214:0.471013:0.250209:0.324326:0.250209:0.013906:0.003421:0.003421:0.010434:0.012007:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.012007:0.010382:0.011118:0.006636
. :@0.471013:0.264214:0.480489:0.264214:0.480489:0.250209:0.471013:0.250209:0.004738:0.004738
2009;15(18):5606-5608. doi:10.1158/1078- :@0.121195:0.278337:0.480489:0.278337:0.480489:0.264332:0.121195:0.264332:0.009989:0.009989:0.009989:0.009989:0.005251:0.009989:0.009989:0.006825:0.009989:0.009989:0.006825:0.005251:0.009989:0.009989:0.009989:0.009989:0.006192:0.009989:0.009989:0.009989:0.009989:0.005251:0.007124:0.012230:0.011716:0.003934:0.005251:0.009989:0.009989:0.005251:0.009989:0.009989:0.009989:0.009989:0.007988:0.009989:0.009989:0.009989:0.009989:0.005756:0.004738
0432.CCR-09-1575.:@0.121195:0.292460:0.274980:0.292460:0.274980:0.278455:0.121195:0.278455:0.009476:0.009476:0.009476:0.009476:0.004738:0.013906:0.013906:0.010382:0.005679:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
11.   Kyle RA, Therneau TM, Rajkumar SV, :@0.084848:0.306583:0.429561:0.306583:0.429561:0.292578:0.084848:0.292578:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010109:0.009168:0.003421:0.011118:0.007098:0.010382:0.012657:0.004738:0.007088:0.007286:0.010434:0.011118:0.005497:0.010434:0.011118:0.011682:0.010399:0.007098:0.007286:0.015719:0.004738:0.007090:0.010382:0.011682:0.003472:0.008586:0.010399:0.016044:0.011682:0.005148:0.007098:0.008518:0.010198:0.004738:0.004738
et al:@0.431921:0.306583:0.471039:0.306583:0.471039:0.292578:0.431921:0.292578:0.011118:0.005798:0.007098:0.011682:0.003421
. :@0.471039:0.306583:0.480515:0.306583:0.480515:0.292578:0.471039:0.292578:0.004738:0.004738
Prevalence of Monoclonal Gammopathy :@0.121195:0.320706:0.480501:0.320706:0.480501:0.306700:0.121195:0.306700:0.010126:0.005075:0.011118:0.009476:0.011682:0.003421:0.011118:0.010434:0.011067:0.011118:0.008313:0.011203:0.005371:0.008313:0.015719:0.011203:0.010434:0.011203:0.011067:0.003421:0.011203:0.010434:0.011682:0.003421:0.008313:0.014915:0.011682:0.016044:0.016044:0.011203:0.011665:0.011682:0.005798:0.010434:0.009168:0.004738
of  Undetermined  Significance. :@0.121195:0.334829:0.390815:0.334829:0.390815:0.320823:0.121195:0.320823:0.011203:0.005371:0.004738:0.006678:0.011203:0.010434:0.011716:0.011118:0.005798:0.011118:0.005614:0.016044:0.003421:0.010434:0.011118:0.011716:0.004738:0.006681:0.008518:0.003421:0.011511:0.010434:0.003421:0.004165:0.004165:0.011067:0.011682:0.010434:0.011067:0.011118:0.004738:0.004738
N  Engl J :@0.397482:0.334829:0.480496:0.334829:0.480496:0.320823:0.397482:0.320823:0.012657:0.004738:0.006678:0.009168:0.010434:0.011511:0.003421:0.011426:0.008244:0.004738
Med:@0.121195:0.348951:0.159748:0.348951:0.159748:0.334946:0.121195:0.334946:0.015719:0.011118:0.011716
. 2006;354(13):1362-1369.  doi:10.1056/:@0.159748:0.348951:0.475736:0.348951:0.475736:0.334946:0.159748:0.334946:0.004738:0.008723:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009496:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.004018:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475
NEJMoa054494.:@0.121195:0.363074:0.251462:0.363074:0.251462:0.349069:0.121195:0.349069:0.012657:0.009168:0.008244:0.015719:0.011203:0.011682:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
12.   Rajkumar SV, Dimopoulos MA, Palumbo A,  :@0.084848:0.377197:0.480489:0.377197:0.480489:0.363192:0.084848:0.363192:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010382:0.011682:0.003472:0.008586:0.010399:0.016044:0.011682:0.005148:0.006158:0.008518:0.010198:0.004738:0.006149:0.012726:0.003421:0.016044:0.011203:0.011665:0.011203:0.010399:0.003421:0.011203:0.006636:0.006158:0.015719:0.012657:0.004738:0.006144:0.010126:0.011682:0.003421:0.010399:0.016044:0.011665:0.011203:0.006158:0.012657:0.004738:0.000000:0.004738
et  al:@0.121195:0.391461:0.170394:0.391461:0.170394:0.377456:0.121195:0.377456:0.011118:0.005798:0.004738:0.012442:0.011682:0.003421
.  International Myeloma  Working :@0.170394:0.391461:0.480505:0.391461:0.480505:0.377456:0.170394:0.377456:0.004738:0.004738:0.012442:0.003866:0.010434:0.005798:0.011118:0.005499:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.017190:0.015719:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.004738:0.012443:0.015635:0.011203:0.005148:0.008586:0.003421:0.010434:0.011511:0.004738
Group  updated  criteria  for  the  diagno-:@0.121195:0.405725:0.475767:0.405725:0.475767:0.391720:0.121195:0.391720:0.014915:0.005078:0.011203:0.010399:0.011665:0.004738:0.006400:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.004738:0.006406:0.011067:0.005148:0.003421:0.005798:0.011118:0.005148:0.003421:0.011682:0.004738:0.006399:0.005371:0.011203:0.005148:0.004738:0.006395:0.005798:0.010434:0.011118:0.004738:0.006402:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.005679
sis  of multiple  myeloma. :@0.121195:0.419989:0.343235:0.419989:0.343235:0.405984:0.121195:0.405984:0.006636:0.003421:0.006636:0.004738:0.007044:0.011203:0.005371:0.011768:0.016044:0.010399:0.003421:0.005798:0.003421:0.011665:0.003421:0.011118:0.004738:0.007042:0.016044:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.004738:0.004738
Lancet Oncol:@0.350265:0.419989:0.471022:0.419989:0.471022:0.405984:0.350265:0.405984:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.011768:0.014864:0.010434:0.011067:0.011203:0.003421
. :@0.471022:0.419989:0.480498:0.419989:0.480498:0.405984:0.471022:0.405984:0.004738:0.004738
2014;15(12):e538-e548.  doi:10.1016/S1470-:@0.121195:0.434253:0.475726:0.434253:0.475726:0.420248:0.121195:0.420248:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.011118:0.009476:0.009476:0.009476:0.005679:0.011118:0.009476:0.009476:0.009476:0.004738:0.004738:0.010134:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.008518:0.009476:0.009476:0.009476:0.009476:0.005679
2045(14)70442-5.:@0.121195:0.448376:0.257944:0.448376:0.257944:0.434371:0.121195:0.434371:0.009476:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
13.   Rawstron AC, Orfao A, Beksac M, :@0.084848:0.462499:0.392787:0.462499:0.392787:0.448494:0.084848:0.448494:0.009479:0.009479:0.004731:0.004738:0.007914:0.000000:0.009869:0.011169:0.013701:0.006123:0.005285:0.004565:0.010690:0.009921:0.005525:0.012144:0.013393:0.004225:0.005525:0.014351:0.005449:0.004858:0.011169:0.010690:0.005525:0.012144:0.004225:0.005525:0.009305:0.010605:0.008073:0.006123:0.011169:0.010553:0.005525:0.015206:0.004225:0.004738
et al:@0.393573:0.462499:0.429578:0.462499:0.429578:0.448494:0.393573:0.448494:0.010605:0.005285:0.005525:0.011169:0.003421
. AND :@0.429065:0.462499:0.480570:0.462499:0.480570:0.448494:0.429065:0.448494:0.004225:0.005525:0.012144:0.012144:0.012729:0.004738
Report of the European Myeloma Network :@0.121195:0.476622:0.480539:0.476622:0.480539:0.462616:0.121195:0.462616:0.009869:0.010605:0.011152:0.010690:0.004635:0.005285:0.008792:0.010690:0.004858:0.008792:0.005285:0.009921:0.010605:0.008792:0.008655:0.009886:0.004565:0.010690:0.011152:0.010605:0.011169:0.009921:0.008792:0.015206:0.008655:0.010605:0.002908:0.010690:0.015531:0.011169:0.008792:0.012144:0.010605:0.005285:0.013701:0.010690:0.004635:0.008586:0.004738
on multiparametric flow cytometry in multiple :@0.121195:0.490745:0.480508:0.490745:0.480508:0.476739:0.121195:0.476739:0.010690:0.009921:0.004644:0.015531:0.009886:0.002908:0.005285:0.002908:0.011152:0.011169:0.004635:0.011169:0.015531:0.010605:0.005285:0.004635:0.002908:0.010553:0.004644:0.003891:0.003891:0.010690:0.013701:0.004642:0.010553:0.008655:0.005285:0.010690:0.015531:0.010605:0.005285:0.004635:0.008655:0.004642:0.002908:0.009921:0.004642:0.015531:0.009886:0.002908:0.005285:0.002908:0.011152:0.002908:0.011116:0.004738
myeloma and related disorders. :@0.121195:0.504867:0.389867:0.504867:0.389867:0.490862:0.121195:0.490862:0.015531:0.008655:0.010605:0.002908:0.010690:0.015531:0.011169:0.009322:0.011169:0.009921:0.011203:0.009322:0.004565:0.010605:0.002908:0.011169:0.005285:0.010605:0.011203:0.009322:0.011203:0.002908:0.006123:0.010690:0.004531:0.011203:0.010605:0.004635:0.006123:0.004225:0.004738
Haemato-:@0.394451:0.504867:0.475748:0.504867:0.475748:0.490862:0.394451:0.490862:0.011169:0.011169:0.010605:0.015531:0.011169:0.005285:0.010690:0.005679
logica. :@0.121195:0.518990:0.179384:0.518990:0.179384:0.504985:0.121195:0.504985:0.002908:0.010690:0.010998:0.002908:0.010553:0.011169:0.004225:0.004738
2008;93(3):431-438. doi:10.3324/hae-:@0.186517:0.518990:0.475700:0.518990:0.475700:0.504985:0.186517:0.504985:0.008963:0.008963:0.008963:0.008963:0.004225:0.008963:0.008963:0.005798:0.008963:0.005798:0.004225:0.008963:0.008963:0.008963:0.005166:0.008963:0.008963:0.008963:0.004225:0.011870:0.011203:0.010690:0.002908:0.004225:0.008963:0.008963:0.004225:0.008963:0.008963:0.008963:0.008963:0.006961:0.009921:0.011169:0.010605:0.005679
matol.11080.:@0.121195:0.533113:0.220554:0.533113:0.220554:0.519108:0.121195:0.519108:0.015531:0.011169:0.005285:0.010690:0.002908:0.004225:0.008963:0.008963:0.008963:0.008963:0.008963:0.004738
14.   Sasson SC, Mcgill K, Wienholt L, :@0.084848:0.547236:0.381816:0.547236:0.381816:0.533231:0.084848:0.533231:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008518:0.011682:0.006636:0.006636:0.011203:0.010434:0.005046:0.008518:0.013906:0.004738:0.005046:0.015719:0.011067:0.011511:0.003421:0.003421:0.003421:0.005046:0.010109:0.004738:0.005034:0.016519:0.003421:0.011118:0.010434:0.010434:0.011203:0.003421:0.005798:0.005046:0.007902:0.004738:0.004738
et al:@0.382088:0.547236:0.419143:0.547236:0.419143:0.533231:0.382088:0.533231:0.011118:0.005798:0.005036:0.011682:0.003421
. Com-:@0.419143:0.547236:0.475750:0.547236:0.475750:0.533231:0.419143:0.533231:0.004738:0.005037:0.013906:0.011203:0.016044:0.005679
parison of the Freelite serum free light chain :@0.121195:0.561359:0.480484:0.561359:0.480484:0.547354:0.121195:0.547354:0.011665:0.011682:0.005148:0.003421:0.006636:0.011203:0.010434:0.003917:0.011203:0.005371:0.003917:0.005798:0.010434:0.011118:0.003917:0.008296:0.005077:0.011118:0.011118:0.003421:0.003421:0.005798:0.011118:0.003917:0.006636:0.011118:0.005148:0.010399:0.016044:0.003917:0.005371:0.005078:0.011118:0.011118:0.003917:0.003421:0.003421:0.011511:0.010434:0.005798:0.003917:0.011067:0.010434:0.011682:0.003421:0.010434:0.004738
(SFLC) assay with serum and urine electro-:@0.121195:0.575482:0.475774:0.575482:0.475774:0.561477:0.121195:0.561477:0.006312:0.008518:0.008296:0.007902:0.013906:0.006312:0.005918:0.011682:0.006636:0.006636:0.011682:0.009168:0.005918:0.014214:0.003421:0.005798:0.010434:0.005918:0.006636:0.011118:0.005148:0.010399:0.016044:0.005906:0.011682:0.010434:0.011716:0.005918:0.010399:0.005148:0.003421:0.010434:0.011118:0.005906:0.011118:0.003421:0.011118:0.011067:0.005798:0.005075:0.011203:0.005679
phoresis/immunofixation  and  the  N  Latex :@0.121195:0.589605:0.480505:0.589605:0.480505:0.575599:0.121195:0.575599:0.011665:0.010434:0.011203:0.005073:0.011118:0.006636:0.003421:0.006636:0.007475:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.004165:0.004165:0.008210:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.004196:0.011682:0.010434:0.011716:0.004738:0.004197:0.005798:0.010434:0.011118:0.004738:0.004197:0.012657:0.004738:0.004194:0.007902:0.011682:0.005798:0.011118:0.008210:0.004738
FLC assay. :@0.121195:0.603728:0.210606:0.603728:0.210606:0.589722:0.121195:0.589722:0.008296:0.007902:0.013906:0.004026:0.011682:0.006636:0.006636:0.011682:0.009168:0.004738:0.004738
Pathology:@0.209905:0.603728:0.294442:0.603728:0.294442:0.589722:0.209905:0.589722:0.010126:0.011682:0.005798:0.010434:0.011193:0.003421:0.011203:0.011511:0.009168
. 2015 Oct;47(6):564-9. :@0.294442:0.603728:0.480460:0.603728:0.480460:0.589722:0.294442:0.589722:0.004738:0.004028:0.009476:0.009476:0.009476:0.009476:0.004037:0.014864:0.011067:0.005798:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738:0.004738
doi:10.1097/PAT.0000000000000316.:@0.121195:0.617850:0.408637:0.617850:0.408637:0.603845:0.121195:0.603845:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.008869:0.011267:0.006072:0.004738:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
15.   Singhal S, Vickrey E, Krishnamurthy J, :@0.084848:0.631973:0.431492:0.631973:0.431492:0.617968:0.084848:0.617968:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008518:0.003421:0.010434:0.011511:0.010434:0.011682:0.003421:0.006123:0.008518:0.004738:0.006123:0.012093:0.003421:0.011067:0.008586:0.005080:0.011118:0.009168:0.006123:0.009168:0.004738:0.006123:0.010109:0.005148:0.003421:0.006636:0.010434:0.010434:0.011682:0.016044:0.010399:0.005148:0.005798:0.010434:0.009168:0.006113:0.008244:0.004738:0.004738
et al. :@0.432878:0.631973:0.480496:0.631973:0.480496:0.617968:0.432878:0.617968:0.011118:0.005798:0.006123:0.011682:0.003421:0.004738:0.004738
The  relationship between  the  serum  free :@0.121195:0.646096:0.480494:0.646096:0.480494:0.632091:0.121195:0.632091:0.007286:0.010434:0.011118:0.004738:0.004572:0.005078:0.011118:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.010434:0.003421:0.011665:0.009322:0.011665:0.011118:0.005798:0.014214:0.011118:0.011118:0.010434:0.004738:0.004574:0.005798:0.010434:0.011118:0.004738:0.004574:0.006636:0.011118:0.005148:0.010399:0.016044:0.004738:0.004575:0.005371:0.005077:0.011118:0.011118:0.004738
light  chain  assay  and  serum  immunofixa-:@0.121195:0.660219:0.475751:0.660219:0.475751:0.646214:0.121195:0.646214:0.003421:0.003421:0.011511:0.010434:0.005798:0.004738:0.003763:0.011067:0.010434:0.011682:0.003421:0.010434:0.004738:0.003763:0.011682:0.006636:0.006636:0.011682:0.009182:0.004738:0.003763:0.011682:0.010434:0.011716:0.004738:0.003765:0.006636:0.011118:0.005148:0.010399:0.016044:0.004738:0.003760:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.004165:0.004165:0.008210:0.011670:0.005679
tion  electrophoresis,  and  the  definition  of :@0.121195:0.674342:0.480501:0.674342:0.480501:0.660337:0.121195:0.660337:0.005798:0.003421:0.011203:0.010434:0.004738:0.003330:0.011118:0.003421:0.011118:0.011067:0.005798:0.005077:0.011203:0.011665:0.010434:0.011203:0.005070:0.011118:0.006636:0.003421:0.006636:0.004738:0.004738:0.003344:0.011682:0.010434:0.011716:0.004738:0.003335:0.005798:0.010434:0.011118:0.004738:0.003330:0.011716:0.011118:0.004165:0.004165:0.010434:0.003421:0.005798:0.003421:0.011203:0.010434:0.004738:0.003329:0.011203:0.005371:0.004738
concordant and discordant free light chain :@0.560589:0.094752:0.919876:0.094752:0.919876:0.080746:0.560589:0.080746:0.010895:0.011032:0.010263:0.010895:0.011032:0.004873:0.011545:0.011511:0.010263:0.005627:0.004841:0.011511:0.010263:0.011545:0.004841:0.011545:0.003250:0.006465:0.010895:0.011032:0.004873:0.011545:0.011511:0.010263:0.005627:0.004841:0.005200:0.004907:0.010947:0.010947:0.004841:0.003250:0.003250:0.011340:0.010263:0.005627:0.004841:0.010895:0.010263:0.011511:0.003250:0.010432:0.004738
ratios. :@0.560589:0.108933:0.612757:0.108933:0.612757:0.094928:0.560589:0.094928:0.004977:0.011511:0.005627:0.003250:0.011032:0.006465:0.004567:0.004738
Blood:@0.611492:0.108933:0.658169:0.108933:0.658169:0.094928:0.611492:0.094928:0.009647:0.003250:0.011032:0.011032:0.011716
. 2009;114(1):38-39. doi:10. 1182/:@0.657998:0.108933:0.915106:0.108933:0.915106:0.094928:0.657998:0.094928:0.004567:0.003477:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.009305:0.009305:0.006140:0.009305:0.006140:0.004567:0.009305:0.009305:0.005508:0.009305:0.009305:0.004567:0.003477:0.011545:0.011032:0.003250:0.004567:0.009305:0.009305:0.004567:0.003477:0.009479:0.009479:0.009479:0.009479:0.007475
blood-2009-02-205807.:@0.560589:0.123115:0.745282:0.123115:0.745282:0.109110:0.560589:0.109110:0.011665:0.003421:0.011203:0.011203:0.011716:0.005679:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
16.   McTaggart MP, Lindsay J, Kearney EM. Re-:@0.524242:0.137297:0.915164:0.137297:0.915164:0.123291:0.524242:0.123291:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.015719:0.011067:0.006395:0.011682:0.011511:0.011511:0.011682:0.005148:0.005798:0.005952:0.015719:0.008015:0.004738:0.005952:0.007902:0.003421:0.010434:0.011716:0.006636:0.011682:0.009168:0.005952:0.008244:0.004738:0.005952:0.010109:0.011118:0.011682:0.005501:0.010434:0.011118:0.009168:0.005952:0.009168:0.015719:0.004738:0.005952:0.010382:0.011118:0.005679
placing  urine protein electrophoresis  with :@0.560589:0.151478:0.919893:0.151478:0.919893:0.137473:0.560589:0.137473:0.011665:0.003421:0.011682:0.011067:0.003421:0.010434:0.011511:0.004738:0.003585:0.010399:0.005148:0.003421:0.010434:0.011118:0.008313:0.011665:0.005080:0.011203:0.005798:0.011118:0.003421:0.010434:0.008313:0.011118:0.003421:0.011118:0.011067:0.005798:0.005077:0.011203:0.011665:0.010434:0.011195:0.005078:0.011118:0.006636:0.003421:0.006636:0.004738:0.003588:0.014214:0.003421:0.005798:0.010434:0.004738
serum free light chain analysis as a first-line :@0.560589:0.165660:0.919895:0.165660:0.919895:0.151655:0.560589:0.151655:0.006636:0.011118:0.005148:0.010399:0.016044:0.005403:0.005371:0.005078:0.011118:0.011118:0.005400:0.003421:0.003421:0.011511:0.010434:0.005798:0.005405:0.011067:0.010434:0.011682:0.003421:0.010434:0.005403:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.005422:0.011682:0.006636:0.005408:0.011682:0.005407:0.004165:0.004165:0.005148:0.006636:0.005798:0.005679:0.003421:0.003421:0.010434:0.011118:0.004738
test for detecting plasma cell disorders of-:@0.560589:0.179254:0.915156:0.179254:0.915156:0.165248:0.560589:0.165248:0.005798:0.011118:0.006636:0.005798:0.006072:0.005371:0.011203:0.005148:0.006072:0.011716:0.011118:0.005798:0.011118:0.011067:0.005798:0.003421:0.010434:0.011511:0.006072:0.011665:0.003421:0.011682:0.006636:0.016044:0.011682:0.006087:0.011067:0.011118:0.003421:0.003421:0.006082:0.011716:0.003421:0.006636:0.011203:0.005047:0.011716:0.011118:0.005148:0.006636:0.006072:0.011203:0.005371:0.005679
fers increased diagnostic accuracy and :@0.560589:0.192847:0.919881:0.192847:0.919881:0.178842:0.560589:0.178842:0.005371:0.011118:0.005148:0.006636:0.010502:0.003421:0.010434:0.011067:0.005078:0.011118:0.011682:0.006636:0.011118:0.011716:0.010502:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.005798:0.003421:0.011067:0.010502:0.011682:0.011067:0.011067:0.010399:0.005148:0.011682:0.011067:0.009168:0.010502:0.011682:0.010434:0.011716:0.004738
potential  health  benefit  to  patients. :@0.560589:0.206441:0.880856:0.206441:0.880856:0.192436:0.560589:0.192436:0.011665:0.011203:0.005798:0.011118:0.010434:0.005798:0.003421:0.011682:0.003421:0.004738:0.005602:0.010434:0.011118:0.011682:0.003421:0.005798:0.010434:0.004738:0.005602:0.011665:0.011118:0.010434:0.011118:0.004165:0.004165:0.005798:0.004738:0.005595:0.005798:0.011203:0.004738:0.005597:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
Am :@0.886461:0.206441:0.919900:0.206441:0.919900:0.192436:0.886461:0.192436:0.012657:0.016044:0.004738
J Clin Pathol:@0.560589:0.220035:0.671562:0.220035:0.671562:0.206029:0.560589:0.206029:0.008244:0.009442:0.013906:0.003421:0.003421:0.010434:0.009442:0.010126:0.011682:0.005798:0.010434:0.011203:0.003421
. 2013;140(6):890-897. doi:10. :@0.671562:0.220035:0.919904:0.220035:0.919904:0.206029:0.671562:0.206029:0.004738:0.009442:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009513:0.005679:0.009476:0.009476:0.009476:0.004738:0.009442:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.004738
1309/AJCP25IHYLEWCAHJ.:@0.560589:0.233628:0.780243:0.233628:0.780243:0.219623:0.560589:0.219623:0.009476:0.009476:0.009476:0.009476:0.007475:0.012657:0.008244:0.013906:0.010126:0.009476:0.009476:0.003866:0.011682:0.010126:0.007902:0.009168:0.016420:0.013906:0.012657:0.011682:0.008244:0.004738
17.   Regelink JC, Minnema MC, Terpos E, :@0.524242:0.247222:0.871249:0.247222:0.871249:0.233217:0.524242:0.233217:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010382:0.011118:0.011511:0.011118:0.003421:0.003421:0.010434:0.008586:0.005940:0.008244:0.013906:0.004738:0.005944:0.015719:0.003421:0.010434:0.010434:0.011118:0.016044:0.011682:0.005940:0.015719:0.013906:0.004738:0.005940:0.006447:0.011118:0.005148:0.011665:0.011203:0.006636:0.005940:0.009168:0.004738:0.004738
et al:@0.872453:0.247222:0.910412:0.247222:0.910412:0.233217:0.872453:0.233217:0.011118:0.005798:0.005940:0.011682:0.003421
. :@0.910412:0.247222:0.919888:0.247222:0.919888:0.233217:0.910412:0.233217:0.004738:0.004738
Comparison of modern and conventional :@0.560589:0.260816:0.919895:0.260816:0.919895:0.246811:0.560589:0.246811:0.013906:0.011203:0.016044:0.011665:0.011682:0.005148:0.003421:0.006636:0.011203:0.010434:0.006777:0.011203:0.005371:0.006777:0.016044:0.011203:0.011716:0.011118:0.005501:0.010434:0.006778:0.011682:0.010434:0.011716:0.006780:0.011067:0.011203:0.010434:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738
imaging techniques in establishing multiple :@0.560589:0.274410:0.919878:0.274410:0.919878:0.260404:0.560589:0.260404:0.003421:0.016044:0.011682:0.011511:0.003421:0.010434:0.011511:0.004779:0.005798:0.011118:0.011067:0.010434:0.010434:0.003421:0.011665:0.010399:0.011118:0.006636:0.004781:0.003421:0.010434:0.004779:0.011118:0.006636:0.005798:0.011682:0.011665:0.003421:0.003421:0.006636:0.010434:0.003421:0.010434:0.011511:0.004779:0.016044:0.010399:0.003421:0.005798:0.003421:0.011665:0.003421:0.011118:0.004738
myeloma-related bone disease: a system-:@0.560589:0.288003:0.915138:0.288003:0.915138:0.273998:0.560589:0.273998:0.016044:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.005679:0.005080:0.011118:0.003421:0.011682:0.005798:0.011118:0.011716:0.006500:0.011665:0.011203:0.010434:0.011118:0.006500:0.011716:0.003421:0.006636:0.011118:0.011682:0.006636:0.011118:0.004738:0.006510:0.011682:0.006500:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.005679
atic review. :@0.560589:0.301597:0.662512:0.301597:0.662512:0.287592:0.560589:0.287592:0.011682:0.005798:0.003421:0.011067:0.006055:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.004738:0.004738
Br J Haematol:@0.663829:0.301597:0.781781:0.301597:0.781781:0.287592:0.663829:0.287592:0.009818:0.005148:0.006055:0.008244:0.006055:0.011682:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421
. 2013;162(1):50-:@0.781781:0.301597:0.915121:0.301597:0.915121:0.287592:0.781781:0.287592:0.004738:0.006055:0.009476:0.009476:0.009476:0.009476:0.004750:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.005679
61. doi:10.1111/bjh.12346.:@0.560589:0.315191:0.771588:0.315191:0.771588:0.301185:0.560589:0.301185:0.009476:0.009476:0.004738:0.004738:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.011665:0.003472:0.010434:0.004738:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
18.   Palumbo A, Avet-Loiseau H, Oliva S, :@0.524242:0.328784:0.869576:0.328784:0.869576:0.314779:0.524242:0.314779:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.011682:0.003421:0.010399:0.016044:0.011665:0.011203:0.006790:0.012657:0.004738:0.006778:0.011400:0.009476:0.011118:0.005798:0.005679:0.007902:0.011203:0.003421:0.006636:0.011118:0.011682:0.010399:0.006790:0.011682:0.004738:0.006790:0.014864:0.003421:0.003421:0.009476:0.011682:0.006790:0.008518:0.004738:0.004738
et al:@0.871628:0.328784:0.910428:0.328784:0.910428:0.314779:0.871628:0.314779:0.011118:0.005798:0.006780:0.011682:0.003421
. :@0.910428:0.328784:0.919904:0.328784:0.919904:0.314779:0.910428:0.314779:0.004738:0.004738
Revised international staging system for :@0.560589:0.342378:0.919893:0.342378:0.919893:0.328373:0.560589:0.328373:0.010382:0.011118:0.009476:0.003421:0.006636:0.011118:0.011716:0.012059:0.003421:0.010434:0.005798:0.011118:0.005501:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.012059:0.006636:0.005798:0.011682:0.011511:0.003421:0.010434:0.011511:0.012059:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.012059:0.005371:0.011203:0.005148:0.004738
multiple myeloma: a report  from interna-:@0.560589:0.355972:0.915156:0.355972:0.915156:0.341966:0.560589:0.341966:0.016044:0.010399:0.003421:0.005798:0.003421:0.011665:0.003421:0.011118:0.008484:0.016044:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.004738:0.008484:0.011682:0.008484:0.005077:0.011118:0.011665:0.011203:0.005148:0.005798:0.004738:0.003736:0.005371:0.005077:0.011203:0.016044:0.008484:0.003421:0.010434:0.005798:0.011118:0.005501:0.010434:0.011682:0.005679
tional myeloma working group. :@0.560589:0.369565:0.829283:0.369565:0.829283:0.355560:0.560589:0.355560:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.006739:0.016044:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.006739:0.014214:0.011203:0.005148:0.008586:0.003421:0.010434:0.011511:0.006727:0.011511:0.005077:0.011203:0.010399:0.011665:0.004738:0.004738
J Clin On-:@0.831265:0.369565:0.915145:0.369565:0.915145:0.355560:0.831265:0.355560:0.008244:0.006739:0.013906:0.003421:0.003421:0.010434:0.006739:0.014864:0.010434:0.005679
col:@0.560589:0.383159:0.586280:0.383159:0.586280:0.369154:0.560589:0.369154:0.011067:0.011203:0.003421
. 2015;33(26):2863-2869.  doi:10.1200/:@0.586280:0.383159:0.915126:0.383159:0.915126:0.369154:0.586280:0.369154:0.004738:0.019892:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009495:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.015185:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475
JCO.2015.61.2267.:@0.560589:0.396753:0.711313:0.396753:0.711313:0.382748:0.560589:0.382748:0.008244:0.013906:0.014864:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
19.   Go  RS,  Vincent  Rajkumar  S,  Affiliations  A. :@0.524242:0.410347:0.919907:0.410347:0.919907:0.396341:0.524242:0.396341:0.009479:0.009479:0.004731:0.004738:0.007914:0.000000:0.014744:0.011032:0.004738:0.004572:0.010211:0.008347:0.004567:0.004738:0.004572:0.011922:0.003250:0.010263:0.010895:0.010947:0.010263:0.005627:0.004738:0.004572:0.010211:0.011511:0.003301:0.008415:0.010228:0.015873:0.011511:0.004977:0.004738:0.004570:0.008347:0.004567:0.004738:0.004572:0.012486:0.005200:0.004079:0.004079:0.003250:0.003250:0.011511:0.005627:0.003250:0.011032:0.010263:0.006465:0.004738:0.004570:0.012486:0.004734:0.004738
How I manage monoclonal  gammopathy :@0.560589:0.423940:0.919928:0.423940:0.919928:0.409935:0.560589:0.409935:0.011511:0.011032:0.014043:0.007697:0.003695:0.007697:0.015873:0.011511:0.010263:0.011511:0.011340:0.010947:0.007697:0.015873:0.011032:0.010263:0.011032:0.010895:0.003250:0.011032:0.010263:0.011511:0.003250:0.004738:0.002951:0.011340:0.011511:0.015873:0.015873:0.011032:0.011494:0.011511:0.005627:0.010263:0.009170:0.004738
of  undetermined  significance. :@0.560589:0.437534:0.815842:0.437534:0.815842:0.423529:0.560589:0.423529:0.011032:0.005200:0.004738:0.003058:0.010228:0.010263:0.011545:0.010947:0.005627:0.010947:0.005451:0.015873:0.003250:0.010263:0.010947:0.011545:0.004738:0.003058:0.006465:0.003250:0.011340:0.010263:0.003250:0.004079:0.004079:0.010895:0.011511:0.010263:0.010895:0.010947:0.004567:0.004738
Blood:@0.818882:0.437534:0.865560:0.437534:0.865560:0.423529:0.818882:0.423529:0.009647:0.003250:0.011032:0.011032:0.011716
. 2017 :@0.865389:0.437534:0.919887:0.437534:0.919887:0.423529:0.865389:0.423529:0.004567:0.007800:0.009305:0.009305:0.009305:0.009479:0.004738
Jan; 131(2):163-173. doi:10.1182 blood-2017- :@0.560589:0.451128:0.919883:0.451128:0.919883:0.437122:0.560589:0.437122:0.008073:0.011511:0.010263:0.004567:0.004191:0.009305:0.009305:0.009305:0.006140:0.009305:0.006140:0.004567:0.009305:0.009305:0.009305:0.005508:0.009305:0.009305:0.009305:0.004567:0.004191:0.011545:0.011032:0.003250:0.004567:0.009305:0.009305:0.004567:0.009305:0.009305:0.009305:0.009305:0.004191:0.011494:0.003250:0.011032:0.011032:0.011545:0.005508:0.009305:0.009305:0.009305:0.009305:0.005730:0.004738
09-807560.:@0.560589:0.464721:0.645273:0.464721:0.645273:0.450716:0.560589:0.450716:0.009305:0.009305:0.005508:0.009305:0.009305:0.009305:0.009305:0.009305:0.009305:0.004738
20.   LeGrand SB, Leskuski D, Zama I. Narrative :@0.524242:0.478315:0.919883:0.478315:0.919883:0.464310:0.524242:0.464310:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.007902:0.011118:0.014915:0.005148:0.011682:0.010434:0.011716:0.007577:0.008518:0.009818:0.004738:0.007577:0.007902:0.011118:0.006636:0.008586:0.010399:0.006636:0.008586:0.003421:0.007577:0.012726:0.004738:0.007577:0.008210:0.011682:0.016044:0.011682:0.007577:0.003866:0.004738:0.007577:0.012657:0.011682:0.005148:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.004738
Review: Furosemide for hypercalcemia: an :@0.560589:0.491909:0.919875:0.491909:0.919875:0.477903:0.560589:0.477903:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.004738:0.004892:0.008296:0.010399:0.005073:0.011203:0.006636:0.011118:0.016044:0.003421:0.011716:0.011118:0.004892:0.005371:0.011203:0.005148:0.004892:0.010434:0.009168:0.011665:0.011118:0.005027:0.011067:0.011682:0.003421:0.011067:0.011118:0.016044:0.003421:0.011682:0.004738:0.004892:0.011682:0.010434:0.004738
unproven yet common practice. :@0.560589:0.505502:0.832921:0.505502:0.832921:0.491497:0.560589:0.491497:0.010399:0.010434:0.011665:0.005077:0.011203:0.009476:0.011118:0.010434:0.003335:0.009168:0.011118:0.005798:0.003335:0.011067:0.011203:0.016044:0.016044:0.011203:0.010434:0.003335:0.011665:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004738:0.004738
Ann Intern :@0.831519:0.505502:0.919914:0.505502:0.919914:0.491497:0.831519:0.491497:0.012657:0.010434:0.010434:0.003335:0.003866:0.010434:0.005798:0.011118:0.005148:0.010434:0.004738
Med:@0.560589:0.519096:0.599142:0.519096:0.599142:0.505091:0.560589:0.505091:0.015719:0.011118:0.011716
.  2008;149(4):259. doi:10.7326/0003-:@0.599142:0.519096:0.915118:0.519096:0.915118:0.505091:0.599142:0.505091:0.004738:0.004738:0.013465:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006332:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.004738:0.018216:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.009476:0.009476:0.009476:0.009476:0.005679
4819-149-4-200808190-00007.:@0.560589:0.532690:0.796509:0.532690:0.796509:0.518685:0.560589:0.518685:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.005679:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
21.   Mhaskar  R,  Kumar  A,  Miladinovic B, :@0.524242:0.546872:0.868125:0.546872:0.868125:0.532866:0.524242:0.532866:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.015719:0.010434:0.011682:0.006636:0.008586:0.011682:0.005148:0.004738:0.002759:0.010382:0.004738:0.004738:0.002757:0.010109:0.010399:0.016044:0.011682:0.005148:0.004738:0.002745:0.012657:0.004738:0.004738:0.002754:0.015719:0.003421:0.003421:0.011682:0.011716:0.003421:0.010434:0.011203:0.009476:0.003421:0.011067:0.007509:0.009818:0.004738:0.004738
et  al.:@0.870896:0.546872:0.915147:0.546872:0.915147:0.532866:0.870896:0.532866:0.011118:0.005798:0.004738:0.002756:0.011682:0.003421:0.004738
 :@0.915147:0.546872:0.919885:0.546872:0.919885:0.532866:0.915147:0.532866:0.004738
Bisphosphonates in  multiple myeloma:  an :@0.560589:0.561053:0.919899:0.561053:0.919899:0.547048:0.560589:0.547048:0.009818:0.003421:0.006636:0.011665:0.010434:0.011203:0.006636:0.011665:0.010434:0.011203:0.010434:0.011682:0.005798:0.011118:0.006636:0.007782:0.003421:0.010434:0.004738:0.003036:0.016044:0.010399:0.003421:0.005798:0.003421:0.011665:0.003421:0.011118:0.007782:0.016044:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.004738:0.004738:0.003034:0.011682:0.010434:0.004738
updated network meta-analysis. :@0.560589:0.575235:0.831283:0.575235:0.831283:0.561230:0.560589:0.561230:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.003616:0.010434:0.011118:0.005798:0.014214:0.011203:0.005148:0.008573:0.003616:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738:0.004738
Cochrane :@0.830171:0.575235:0.919900:0.575235:0.919900:0.561230:0.830171:0.561230:0.013906:0.011203:0.011067:0.010434:0.005148:0.011682:0.010434:0.011118:0.004738
Database Syst Rev:@0.560589:0.589417:0.712510:0.589417:0.712510:0.575411:0.560589:0.575411:0.012726:0.011682:0.005798:0.011682:0.011665:0.011682:0.006636:0.011118:0.003917:0.008518:0.009168:0.006636:0.005798:0.003917:0.010382:0.011118:0.009476
. 2017 December. doi:10. :@0.712510:0.589417:0.919875:0.589417:0.919875:0.575411:0.712510:0.575411:0.004738:0.003908:0.009476:0.009476:0.009476:0.009476:0.003917:0.012726:0.011118:0.011067:0.011118:0.016044:0.011665:0.011118:0.003891:0.004738:0.003908:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.004738
1002/14651858.CD003188.pub4.:@0.560589:0.603598:0.822679:0.603598:0.822679:0.589593:0.560589:0.589593:0.009476:0.009476:0.009476:0.009476:0.007475:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738:0.013906:0.012726:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738:0.011665:0.010399:0.011665:0.009476:0.004738
22.   Alemu A, Richards JO, Oaks MK, :@0.524242:0.617780:0.830400:0.617780:0.830400:0.603775:0.524242:0.603775:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.012657:0.003421:0.011118:0.016044:0.010399:0.004690:0.012657:0.004738:0.004687:0.010382:0.003421:0.011067:0.010434:0.011682:0.005042:0.011716:0.006636:0.004704:0.008244:0.014864:0.004738:0.004693:0.014864:0.011682:0.008586:0.006636:0.004704:0.015719:0.010109:0.004738:0.004738
et al:@0.830342:0.617780:0.867051:0.617780:0.867051:0.603775:0.830342:0.603775:0.011118:0.005798:0.004690:0.011682:0.003421
. Vac-:@0.867051:0.617780:0.915140:0.617780:0.915140:0.603775:0.867051:0.603775:0.004738:0.004692:0.010232:0.011682:0.011067:0.005679
cination in multiple myeloma: review of :@0.560589:0.631962:0.919881:0.631962:0.919881:0.617956:0.560589:0.617956:0.011067:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.010707:0.003421:0.010434:0.010707:0.016044:0.010399:0.003421:0.005798:0.003421:0.011665:0.003421:0.011118:0.010707:0.016044:0.009168:0.011118:0.003421:0.011203:0.016044:0.011682:0.004738:0.010707:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.010707:0.011203:0.005371:0.004738
current literature. :@0.560589:0.646143:0.711124:0.646143:0.711124:0.632138:0.560589:0.632138:0.011067:0.010399:0.005148:0.005071:0.011118:0.010434:0.005798:0.009048:0.003421:0.003421:0.005798:0.011118:0.005148:0.011682:0.005798:0.010399:0.005071:0.011118:0.004738:0.004738
Clin Lymphoma Myelo-:@0.715435:0.646143:0.915162:0.646143:0.915162:0.632138:0.715435:0.632138:0.013906:0.003421:0.003421:0.010434:0.009048:0.007902:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.009048:0.015719:0.009168:0.011118:0.003421:0.011203:0.005679
ma Leuk:@0.560589:0.660325:0.631401:0.660325:0.631401:0.646320:0.560589:0.646320:0.016044:0.011682:0.005080:0.007902:0.011118:0.010399:0.008586
. 2016;16(9):495-502. doi:10.1016/J.:@0.631401:0.660325:0.915150:0.660325:0.915150:0.646320:0.631401:0.646320:0.004738:0.005068:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009495:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.005095:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.008244:0.004738
CLML.2016.06.006.:@0.560589:0.674507:0.710252:0.674507:0.710252:0.660501:0.560589:0.660501:0.013906:0.007902:0.015719:0.007902:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738